Exchange: NASDAQ·Updated 07:30 PM EDT

IMCR News

News
all
press releases
Immunocore Hldgs Q2 2026 Earnings Call Transcript
Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access toread more...
Benzinga
Immunocore Hldgs Q2 2026 Earnings Call Transcript
Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access toread more...
Benzinga
More News
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Zacks
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
Strong demand for Kimmtrak is fueling Immunocore's growth, while potential label expansion and late-2026 data could add further upside.
Zacks
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Zacks
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.
Zacks
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
Zacks
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
Zacks
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 77.9% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Kimmtrak anchors IMCR today, but its broader T-cell receptor platform is targeting larger cancer, infectious disease and autoimmune markets.
Zacks
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
Kimmtrak's sales growth supports IMCR, but premium valuation and reliance on one product keep investors focused on upcoming pipeline catalysts.
Zacks

Advertisement|Remove ads.